Shock Following Myocardial Infarction: A Clinical Survey of 140 Cases

Area of Science:

• Cardiology
• Internal Medicine
• Critical Care Medicine

Background:

• Acute myocardial infarction (AMI) is a leading cause of mortality.
• Cardiogenic shock is a severe complication of AMI with high fatality rates.
• The role of vasopressors like noradrenaline in managing cardiogenic shock remains an area of investigation.

Purpose of the Study:

• To evaluate the impact of intravenous noradrenaline on mortality in patients with cardiogenic shock following AMI.
• To analyze trends in the incidence of cardiogenic shock over a 10-year period.
• To investigate patient characteristics associated with mortality in cardiogenic shock.

Main Methods:

• Retrospective review of all acute myocardial infarction admissions over 10 years.
• Identification of patients meeting criteria for cardiogenic shock.
• Comparison of mortality rates between patients receiving and not receiving intravenous noradrenaline.
• Autopsy data analysis for previous myocardial infarction incidence.

Main Results:

• 83% mortality rate in 140 patients with cardiogenic shock.
• No significant difference in mortality between patients treated with intravenous noradrenaline (n=95) and those not (n=45).
• Patients dying from cardiogenic shock were younger and had a lower incidence of prior healed myocardial infarction.

Conclusions:

• Intravenous noradrenaline did not alter mortality in this cardiogenic shock cohort.
• A decline in cardiogenic shock incidence may be linked to earlier noradrenaline use.
• Despite reduced shock incidence, overall AMI mortality remained unchanged.